Blosozumab Explained

Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.[1] Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect.[2]

Blosozumab was developed by Eli Lilly and Company.

Notes and References

  1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 . WHO Drug Information . 25 . 2 . 2011 .
  2. McColm J, Hu L, Womack T, Tang CC, Chiang AY . Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women . Journal of Bone and Mineral Research . 29 . 4 . 935–43 . April 2014 . 23996473 . 10.1002/jbmr.2092 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Blosozumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.